

Please amend claim 14 as follows:

C2 14 (Once amended). The method of claim 5 wherein the second intracellular loop of said orphan receptor comprises the following sequence:

XRY

wherein X can be any amino acid other than D; R is arginine, and Y is tyrosine.

Please cancel claims 19-32, without prejudice.

Please amend claim 33 as follows:

Sub E1 33 (Twice amended). A method for directly identifying a candidate compound as a compound having activity selected from the group consisting of inverse agonist activity[, partial agonist activity] and agonist activity[,] to a non-endogenous constitutively activated G protein coupled cell surface orphan receptor, comprising the steps of:

- C3
- (a) contacting a candidate compound with a non-endogenous constitutively activated G protein coupled cell surface orphan receptor; [and]
 - (b) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound has inverse agonist activity[, partial agonist activity,] or agonist activity to said receptor[.]; and
 - (c) directly identifying a compound of step (b) having inverse agonist activity as an inverse agonist to said receptor, or having agonist activity as an agonist to said receptor.

Please cancel claims 35-38, without prejudice.

Please amend claim 39 as follows:

C4 39 (Twice amended). A method for directly identifying a candidate compound as a compound having activity selected from the group consisting of inverse agonist activity[, partial agonist activity] and agonist activity[,] to an endogenous constitutively activated G protein coupled cell surface orphan receptor, comprising the steps of:

- (a) contacting a candidate compound with an endogenous constitutively activated G protein coupled cell surface orphan receptor; [and]
- (b) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound has inverse agonist